Not recruitingISRCTN83050762
Quetiapine augmentation of a serotonin reuptake inhibitor in treatment resistant OCD: a multi-site, placebo-controlled study
Research studyCanada + South Africa
Understand this study
- Listed locations
- Canada · South Africa
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Not recruiting
- Enrollment listed in the registry
- Not clearly listed
- Sponsor
- AstraZeneca (South Africa)
- Sponsor type
- Unknown or unclear
- Study type
- Other
- Intervention type
- Other / unclear
- Locations
- Canada, South Africa
- Age range
- Not clearly listed
- Official registry ID
- ISRCTN83050762
- Official title
Show the full official title
Quetiapine augmentation of a serotonin reuptake inhibitor in treatment resistant OCD: a multi-site, placebo-controlled study
Recruitment & locations
Not recruitingThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Canada · South Africa
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is AstraZeneca (South Africa).
Is this study still recruiting?
The registry lists this study as not recruiting.
